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A b s t r A c t
Background: Due to the emergence of drug resistance in herpes simplex virus type 1 
(HsV-1), researchers are trying to find other methods for treating herpes simplex virus 
type 1 infections. Probiotic bacteria are effective in macrophage activation and may have 
antiviral activities. 
Objective: this study aimed at verifying the direct effect of Lactobacillus rhamnosus, a probiotic 
bacterium, in comparison with Escherichia coli, a non-probiotic one, on HsV-1 infection, and 
determining its effect on macrophage activation for in vitro elimination of HsV-1 infection. 
Methods: the above bacteria were introduced into HsV-1 infected Vero cells, and their effects 
were examined using both Mtt and plaque assay. to determine macrophage activation 
against in vitro HsV-1 infection, J774 cells were exposed to these bacteria; then, macrophage 
viability was examined with the Mtt method, and tumor necrosis factor alpha (tnf-α), 
interferon-gamma (ifn-γ), and nitric oxide (no) assessments were performed using the 
ELisA method.
Results: A significant increased viability of macrophages was observed (p < 0.05) in the 
presence of Lactobacillus rhamnosus before and after HsV-1 infection when compared with 
Escherichia coli as a non-probiotic bacterium. However, tumor necrosis factor α concentration 
produced by Escherichia coli-treated J774 cells was significantly higher than Lactobacillus 
rhamnosus-treated J774 cells (p < 0.05). interferon-gamma and no production were not 
different in the groups treated with Escherichia coli or with Lactobacillus rhamnosus. 
Conclusion: the results of this study indicate that Lactobacillus rhamnosus enhances 
macrophage viability for HsV-1 elimination and activation against HsV-1 more effectively, 
when compared with non-probiotic Escherichia coli. it also seems that receptor occupation 
of macrophage sites decreases HsV-1 infectivity by both of the studied bacteria.
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Introduction
Herpes simplex virus-1 (HsV-1) can cause two types of infection. 
the initial infection, most often asymptomatic, involves the 
epithelial cells and can be latent in the sensory nerve ganglia. 
in a few infected individuals, the latent viruses are activated 
under different stress conditions, for instance sunshine, 
hormonal changes, fever, appearing as cold sore.1 HsV-1 is the 
agent of many diseases such as gingivostomatitis, sore throat 
(pharyngitis), herpetic whitlow, keratoconjunctivitis, herpes 
encephalitis and meningitis. in immunosuppressed patients, it 
can be a chronic destructive process.1-3 both specific and non-
specific defense mechanisms against HsV-1 are important. Host 
genetic background, macrophages, nK cells, and t-cells and 
antibodies are important factors in the defense against HsV-1.1,2 
Macrophage activation can also reduce infection by the virus.4 
Anti-viral drugs including acyclovir, vidarabine, famciclovir, 
valacyclovir, pencyclovir are widely used in the treatment of 
HsV-1 infection.1,2 nowadays, the occurrence of mutations in viral 
DnA polymerase and thymidine kinase has led to an increase 
in drug resistance to nucleoside analogs such as acyclovir.4,5 to 
find appropriate alternatives, researchers suggest seeking new 
chemical and plant sources of therapy for HsV-1 infections.6-10
considering the role of specific and non-specific host 
defenses against HsV-1, some therapies can work to 
strengthen and activate the innate and specific immune 
system components against HsV-1.11 coordinating operations 
of macrophages in anti-herpetic response occur during the first 
hour of virus invasion. the first defensive line is production 
and secretion of cytokines such as type i interferon (ifn) and 
tumor necrosis factor (tnf). subsequently, iL-12 and ifn-γ 
are produced, thereby resulting in natural killer cell and 
macrophage activation. the production of active oxygen radicals 
(ros) and of no are auxiliary mechanisms to improve anti-viral 
response.12-15 Macrophages have receptors for molecules such 
as lipopolysaccharide, mannose, and unmethylated cPG repeats 
of bacteria.16 signals resulting from the combination of these 
factors increase the secretion of a wide range of cytokines, 
which strengthen the innate immune system and activate the 
specific immune system, especially t cells, against pathogens 
such as viruses17,18 Among them, inf-γ launches various 
activities in macrophages, including antimicrobial activity, 
causing eradication of intracellular pathogens. Macrophage 
activity is one of the first steps in preventing virus proliferation 
(HiV, HsV, VZV) in infected cells. Also, antigen processing and 
presentation to th1 lymphocytes by macrophages induce cell-
mediated immunity.15-18 no induction of the macrophages in 
an inflammatory response is also an innate immune defense 
system.19 no has different tasks such as killing infected cells, 
tumor cells, and parasitic pathogens. Antiviral effect of no in 
various viral infections has also been documented.20
Probiotic bacteria such as Lactobacillus and Bifidobacterium, 
which typically ferment dairy foods in human and animal 
digestive tracts, can balance the immune system and increase the 
specific and non-specific immune responses. they are important 
as immunomodulatory bacteria in the body’s defense against 
pathogens such as viruses (HiV, VZV).21,22 Various studies have 
shown that Lactobacillus rhamnosus (strain GG), a species of probiotic 
bacteria, has beneficial effects in treating rotavirus gastroenteritis 
in infants.23,24 several studies from in vitro systems, animal 
models, and humans, suggests that probiotics can enhance both 
specific and nonspecific immune responses.25,26
 in a study, it was demonstrated that consumption of lactic 
acid bacteria in guinea pigs has anti-influenza effects. Also, 
taking 1 × 109 cfu/mL of lactic acid bacteria decreases genital 
herpes complications caused by HsV-2.27 in another study, 
the effect of probiotic bacteria for prevention and treatment 
of viral diarrhea caused by rotavirus, astrovirus, calicivirus, 
enteric adenovirus and coronavirus was reviewed, and the 
helpful role of probiotic bacteria in limiting viral diarrhea 
was documented.26 in an in vitro study, it was demonstrated 
that probiotic bacteria increase the antiviral response against 
vesicular stomatitis virus (VsV) by activating macrophages.11
so, the emergence of antiviral drug resistance observed 
in HsV-1 makes it necessary to find other alternatives for 
treating HsV-1 infection. considering the important role of 
macrophages in eliminating viral infections and the effective 
role of probiotic bacteria in the removal of viral infections 
(including HsV), this study aimed to investigate: 1) the direct 
effect of Lactobacillus rhamnosus, a probiotic bacterium, on 
HsV-1; and 2) its effect on macrophage activation for in vitro 
elimination of HsV-1 infection. in this way, the possible use 
of probiotics to inhibit HsV-1 infection would be scientifically 
proven as an alternative treatment.
Methods
Bacteria and cytotoxic assays
Lyophilized standard strains of Lactobacilli rhamnosus (Ptcc 
1637) and E. coli (Ptcc 25923) were provided by the iranian 
research organization for science and technology, tehran, 
iran. Lactobacilli rhamnosus was cultured to log phase growth 
in L-cystein HcL supplemented by Man rogosa sharp (Mrs) 
broth (Himedia – india) under anaerobic conditions at 37°c, 
overnight. in order to isolate single bacterial colonies, the 
harvested broth was transferred to Mrs agar (Himedia – india) 
and incubated under the described conditions for 24-36 hours.
the maximum number of bacteria introduced into the antiviral 
assays was determined as the highest number of bacteria that was 
not cytotoxic to the macrophage cell line J774 (data not shown). 
the value was determined to be 1 × 108 cfU/mL of each strain.
to prepare 1 × 108 cfU/mL of viable bacteria for stimulation 
experiments, isolated colonies were suspended in Pbs. the 
optical density (oD) was measured by spectrophotometer at 
530 nm. colony concentration was determined via internal 
Mcfarland standard oD comparison.
the percentage of adherent bacteria was determined by 
co-incubation of bacteria with the macrophage cell line for 
90 minutes, at 37°c, in a humidified atmosphere of 5% co2. 
non-adherent bacteria were removed from the cell cultures 
by washing twice with Pbs. the cells were harvested and the 
percentage of adherent bacteria was determined by agar plate 
counts of serially diluted suspensions plated on Mrs agar. in 
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order to prepare inactivated bacterial suspension, the culture 
was frozen at 1 × 108 cfU/mL count and thawed in boiling 
water for 3 cycles. Also, E. coli was grown to log phase growth 
in EMb agar (Merck – Germany) at 37°c overnight.11
Virus
HsV-1 was isolated from the lip lesions of a patient and was 
confirmed by neutralization test using guinea pig anti-HsV-1 
serum (niH – UsA) and monoclonal anti-HsV-1 antibodies 
against HsV glycoproteins D and G.28
HsV-1 was grown to a titer of 106/mL in Vero cell line, in the 
maintenance medium of Dulbeccos modified Eagles growth 
medium (DMEM, sigma) supplemented with 2% fetal bovine 
serum (Gibco – Germany), 0.14% (v/v) sodium bicarbonate, 
100 U/mL penicillin, 100 μg/mL streptomycin sulphate, and 
0.25 μg/mL amphotericin b. the virus was stored at −70°c until 
used. for the antiviral assay, 100 μL of the virus with a plaque-
forming unit of 50% per mL was used.
Cells
the murine monocyte/macrophage cell line J774 cells were 
obtained from the Pasteur institute, tehran, iran. they 
were grown until confluence in rPMi 1640 media (Gibco – 
Australasia) containing 10% fetal bovine serum (fbs), and 
supplemented with 100 μg/mL streptomycin and 100 iU/mL 
penicillin in tissue culture flasks (nunc – Denmark), at 37°c, 
in an atmosphere of 5% co2.
Also, confluent Vero African green monkey kidney cells (razi 
institute, Hesarak – iran) were prepared in DMEM, supplemented 
with 8% fetal calf serum. for Vero cells maintenance, DMEM 
medium was used supplemented with only 2% fetal calf serum. 
in order to evaluate cell viability, the trypan blue dye (Merck – 
Germany) exclusion method was performed.29
Plaque assays
Possible inhibitory effect of the studied bacteria on HsV-1 
was investigated using plaque reduction assay, as previously 
described.10 Phosphate buffered saline (Pbs)-washed confluent 
Vero cells in 24-well plates (nunc – Denmark) were treated 
with the maintenance medium containing plates (nunc – 
Denmark). they were treated first with the maintenance 
medium, containing 1 × 108 cfU/mL of live or bacterial debris 
suspension of E. coli and L. rhamnosus, for 90 min, and then 
with 50 PfU/100μL HsV-1, for 40 min. in another series of the 
experiments under the described conditions, the cells were 
first exposed to the virus and then to the bacteria; they 
were also simultaneously exposed to the bacteria and virus. 
After removing these treatments, the monolayers were 
infected with 50 PfU/mL of HsV-1 for one hour. subsequently, 
the monolayers were overlaid with 1% carboxymethyl cellulose 
(cMc) in the maintenance medium, and were incubated at 
37°c with 5% co2 for four days. controls for each series of the 
experiment included uninfected cell monolayers, and virus-
infected treated or untreated cells with the bacteria. the virus 
plaques formed on the cells were fixed with methanol for 
10 min, and stained with 0.5% crystal violet solution.28
MTT assay
the Mtt assay (3-4, 5 dimethyl thiazol- 2 yl)-2, 5- diphenyl 
tetrazolium bromide) (sigma – UsA) was used to assess the living 
cells according to measured active mitochondrial metabolic 
function. the assay was able to indicate potential beneficial 
effects of antiviral agents.29 briefly, after the incubation 
period (24 hours at 37°c in presence of 5% co2) on a 96-well 
plate containing 90 μL of serial dilution of cell suspension 
with the cell concentration of 1 × 105, 5 × 104, 2.5 × 104, 
1.25 × 104, 6,250 cell/mL, the wells were washed. then, 10μL 
of ready Mtt dye was added. the plate was incubated at 37°c 
for 3-4 hours. After this period, the contents were centrifuged 
for 10 min at 300 rpm, the supernatant was removed, and the 
cells were suspended in 100 μL DMso. the optical density of 
each well was determined at 570 nm, using an ELisA reader.30
Assays of the effect of J774 cell culture supernatant treated 
with L. rhamnosus on HSV-1 infected Vero cell
1 × 105 cell/mL of J774 cells were incubated in a 24-wells 
plate, at 37°c, in the presence of 5% co2 for 24 hours; 
1 × 108 cfU/ mL living and/or bacterial debris suspension was 
added to a separate well plate. Prior to the Pbs washing, the 
cells were remained at 37°c for 90 min to adhere the bacteria 
to the cells. the plate was incubated at 37°c in the presence 
of 5% co2 for another 48 hours until no and other cytokines 
were released. in the next stage, 90 μL of the supernatant of 
J774 cells treated with bacteria were transferred to the plate 
containing 50 PfU/100 μL HsV-1 infected Vero cells. After 45 
min, the percentage of viable cells was measured using the 
Mtt test, as described above. the wells containing non-
infected Vero cells and free supernatant of J774 cells treated 
with bacteria were considered as controls.
Assays of the effect of L. rhamnosus on J774 cell line activation 
against HSV-1
24-hour-incubated plates of 1 × 105 cell/mL of J774 cells were 
inoculated with 1 × 108 cfU/mL living and/or bacterial debris 
suspension for 90 min, and then infected with 50 PfU/100 
HsV-1 for 40 min.
in another series of experiments, the cells were infected 
with 50 PfU/100 μL HsV-1 for 40 min, and then inoculated with 
1 × 108 cfU/mL living and/or bacterial debris suspension for 
90 min. the plates were incubated at 37°c in the presence of 
5% co2 for 24 hours. the percentage of metabolically active 
cells was determined via Mtt test, as described. the well 
containing neither virus nor bacterium was considered as 
the negative control. Prior to performing the Mtt test, the 
supernatant of all the cells was collected to measure no, infγ, 
and tnfα levels.
NO measurement
to measure no concentration, levels of released no were 
measured using the Griess reaction.31 100 μL of supernatant 
from incubated 1 × 108 cell/mL of J774 cells only, J774 cells 
treated with L. rhamnosus, inactivated L. rhamnosus, E.coli 
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and inactivated E. coli, at 37°c in the presence of 5% co2 for 
48 hours, were added to the ELisA plate separately, with 
100 μL of modified Griess reagent (Merck – Germany). After 
10 min incubation at room temperature, the absorbance at 
450 nm was measured. the concentration of no was calculated 
using nano2 standard curve.
INFγ and TNFα levels determination
infγ and tnfα levels were detected using a commercial 
enzyme-linked immunosorbent assay (ELisA) kit (bender 
Medsystem – UsA) according to the manufacturer’s instructions. 
100 μL of supernatant from incubated 1×108 cell/mL of J774 
cells only, J774 cells treated with L. rhamnosus, inactivated 
L. rhamnosus, E. coli and inactivated E. coli at 37°c in the presence 
of 5% co2 for 48 hours were added to the ELisA plate separately.
Statistical analysis
All statistical analyses were performed using the statistical 
Package for social sciences (sPss) version 11.5 software 
(chicago, iL, UsA). the difference between the two groups 
(L. rhamnosus and E. coli) was tested using the Mann-
Whitney test. the J774 cells only were used as a control. 
p-values less than or equal to 0.05 were considered as 
statistically significant.
Results 
L. rhamnosus significantly enhanced HSV-1 infected Vero cells 
viability
compared to HsV-1 infected control cells, L. rhamnosus 
significantly increased cell viability of the HsV-1 infected Vero 
cells either pre or post HsV-1 infection [(49 ± 1.1%, 47.6 ± 1.5%, 
respectively) (41.7 ± 1.1%) (p ≤ 0.05 )]. E. coli showed a similar 
effect on the elevation of Vero cells viability (fig. 1).
L. rhamnosus reduced HSV-1 plaques on Vero cells
compared to HsV-1-infected Vero cells (83.3 ± 2.08) as the 
control, significantly lower numbers of plaques were detected 
in the Vero cell culture treated with L. rhamnosus either 
pre or post HsV-1 infection (68.1 ± 1, 71 ± 2, respectively). 
A statistically similar reduction of HsV-1 plaques was observed 
in the Vero cells exposed to E. coli. (table 1).
Experiment conditions 
 
Mean numbers of  
plaques ± SD 
Vero cell monolayer 0 
Vero + HsV-1 83.3 ± 2.08
Vero + HsV-1 + L. rhamnosus 71 ± 2.0 
Vero + HsV-1 + E. coli 73 ± 3.0 
Vero + L. rhamnosus 0 
Vero + E. coli 0
Vero + L. rhamnosus + HsV-1 68 ± 1.0
Vero + E. coli + HsV-1 69 ± 0.57 
Table 1 - Comparison of number of plaques of Vero cells 
infected with HSV-1 in different experiments
Supernatant of treated macrophage J774 culture with 
L. rhamnosus and E. coli significantly increased Vero cell viability
As shown in fig. 2, the supernatant of pre-treated macrophage 
J774 cells with live and/or inactive L. rhamnosus significantly 
increased the Vero cell viability in comparison to cells infected 
with the virus only (74.9 ± 0.95 – 51 ± 2.9) (p ≤ 0.05). However, 
E. coli treatment caused a lower Vero cell viability, but the 
difference was not significant (p ≥ 0.05).
Fig. 1 - Comparison of Vero cells viability percentages 
under different conditions using the MTT test.
Fig. 2 - Comparison of cell viability percentages of HSV-1 
infected Vero cells affected by J774 culture supernatant 
treated with L. rhamnosus and E. coli suspensions.  
A, Vero cells; B, Vero cells+HSV-1; C, Vero cells+HSV-1+ 
J774 supernatant treated with live L. rhamnosus; D, Vero 
cells+HSV-1+ J774 supernatant treated with live E. coli;  
E, Vero cells+HSV-1+ J774 supernatant treated with  
inactive L. rhamnosus; F, Vero cells+HSV-1+ J774 
supernatant treated with inactive E. coli; G, Vero cells+ J774 
supernatant.
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L. rhamnosus caused increased viability of macrophage J774 
cells infected with HSV-1
As shown in fig. 3, a significantly increased viability of J774 
cells was observed after L. rhamnosus treatment of J774 cells 
pre and post-infection with HsV-1 versus non-treated J774 cells 
and E. coli-treated J774 cells (p ≤ 0.05).
Pro-inflammatory cytokines and NO production were stimulated 
in the presence of bacteria
co-incubation of J774 cells with suspension of either live 
or inactive L. rhamnosus or E. coli stimulated macrophages 
to produce no, tnf-α and ifn-γ (table 2). E. coli caused 
significantly higher tnf-α production compared to 
L. rhamnosus (p = 0.019). A remarkable induction of tnf-α 
production was observed by J774 cells exposed to live E. coli 
suspension pre and post infection with HsV-1, as well as 
to inactive E. coli (p = 0.027). such effect was not seen with 
L. rhamnosus. Live or inactive suspensions of L. rhamnosus or 
E. coli did not stimulate no or ifn-γ secretion in HsV-1 
infected J774 cells.
Discussion
clinical interventional studies have identified those specific 
probiotics that have antiviral effects via shortening of the 
infectious period or decreasing the risk of certain viral 
infection. the best finding was the beneficial influence of 
probiotics on viral diarrhea in infants and children.32
in a study on anti HsV-2 effect of selected vaginal 
Lactobacillus strains (L. brevis cD2, L. salivarius fV2, L. 
plantarum fV9), conti et al. demonstrated the inhibitory 
effect of living bacterial cells on HsV-2, through several 
mechanisms, including interference with early steps of 
virus replication such as binding/entry, and the production 
of lactic acid and hydrogen peroxide, with a direct antiviral 
effect.33
there are also two separate reports demonstrating the 
protective effects of various lactic acid bacteria on VsV-
infected porcine epithelial and macrophage cell lines.34,11
With regard to the proven antiviral effect of probiotic 
strains and to researchers’ attempts to create an appropriate 
protocol to treat or prevent HsV-1 infection, we decided to 
test a probiotic bacterium as a candidate for such a purpose.
in this study we evaluated the in vitro effects of 
L. rhamnosus, a probiotic bacterium, directly on HsV-1 
infections, and its influence on stimulation of no release and 
tnf-α and ifn-γ production as pro-inflammatory cytokines 
following L. rhamnosus activation of murine monocyte/
macrophage J774 cell line.
our results clearly demonstrated that L. rhamnosus exposure 
enhanced the viability of J774 cell line up to 90%, which is 
remarkable in comparison to the results reported by ivec et 
Experiment conditions NO (μg/mL)  
Mean± SD 
IFNγ (pg/mL)  
Mean ± SD 
TNF-α (pg/mL) 
Mean ± SD 
J774 0 7.1 ± 0.57 17.3 ± 2.08 
J774 + HsV-1 0.11 ± 0.015 14.5 ± 0.73 286 ± 4.6 
J774 + L. rhamnosus 0.14 ± 0.01 14.1 ± 1.52 205 ± 2.88 
J774 + E. coli 0.12 ± 0.02 16.1 ± 1.52 452 ± 2.51
J774 + L. rhamnosus + HsV-1 0.13 ± 0.01 16.6 ± 1.52 236 ± 2.51 
J774 + HsV-1 + L. rhamnosus 0.11 ± 0.01 16 ± 1.15 276 ± 2.3 
J744 + E. coli + HsV-1 0.11 ± 0.01 14.1 ± 1.52 323 ± 3.0 
J774 + HsV-1 + E. coli 0.12 ± 0.01 15.1 ± 1.52 372 ± 3.0
J774 + inactive L. rhamnosus + HsV-1 0.11 ± 0.01 13.1 ± 1.52 227 ± 2.64 
J774 + inactive E. coli + HsV-1 0.11 ± 0.01 13 ± 1.0 368 ± 3.05 
Table 2 - The levels of TNF-α, NO and IFN-γ measured by ELISA in different conditions on this study
Fig. 3 - J774 cells viability treated with Lb .rhamnosus and  
E. coli suspensions; A, J774; B, J774 + HSV-1; C, J774 +  
Lb .rhamnosus; D, J774 + E. coli; E, J774 + L.rhamnosus +  
HSV-1; F, J744 + E. coli + HSV-1; G, J774 + HSV-1 +  
L. rhamnosus; H, J774 + HSV-1 + E. coli; I, J774 + inactive  
L. rhamnosus + HSV-1; J, J774 + inactive E. coli + HSV-1.
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al. (30% viability of VsV infected 3D4/21 cell line). the cause 
of viability increase can be due to difference of cell line, VsV 
infectious capacity versus HsV-1, or probiotic species between 
the two studies. Also, we detected more protective effect of live 
bacteria than inactive bacteria on the exposure of viral infected 
macrophages, a finding consistent with ivec et al.’s report. 
A mechanism involved in the protective effect of probiotic 
bacteria against virus particles is competition for cell surface 
attachment. this has already been proven in vitro, and reported 
as a feasible mechanism for the protection of cells in the case 
of VsV infection.6,11
Preservation of a cpG motif in bacterial DnA during 
inactivation of bacteria has been reported to suppress the 
apoptotic pathways and enhance the cell viability.11,35 
our study demonstrated the higher viability of HsV-1 
infected macrophage J774 cells treated with L. rhamnosus 
when compared to E. coli treatment, although the reason is 
unclear. one explanation of lower cells viability in the case of 
E. coli exposure compared to L. rhamnosus can be related to 
increased tnf-α production induced by E. coli, which causes 
more cell apoptosis. We showed more tnf-α production induced 
by E. coli exposure pre- and post-HsV-1 infection of the cells 
compared to L. rhamnosus. the presence of lipopolysaccharide in 
the cell wall of E. coli is a potential stimulator for tnf release.36
increased viability of infected Vero cells by a supernatant of 
J774 cells exposed to L. rhamnosus might result from no, tnf-α 
and ifn-γ production, as pro-inflammatory cytokines.11,15 this 
suppressed HsV-1 proliferation. no release is another antiviral 
mechanism, which has also been previously reported. in fact, 
significant increase of no release was reported in co-incubated 
macrophage exposed to probiotic bacteria in the presence of 
ifn-γ; however, ivec et al. stated that ifn-γ is not an important 
factor in the stimulation of no release.11,37
in our study, J774 cells co-incubated with live or inactive 
L. rhamnosus or E. coli were capable of inducing tnf-α, ifn-γ 
and no production. concentration of ifn-γ and its dependent 
mediator, no, is lower than those of a previous report. 
However, in that report, probiotic bacteria were applied with 
exogenous ifn-γ, so it can be concluded that the simultaneous 
presence of ifn-γ with probiotic bacteria might be necessary 
for the production of high levels of no.37 in the case of 
inactive bacteria, cell wall components such as peptidoglycan, 
lipoteichoic acid and cpG motifs can induce no, tnf-α and 
ifn-γ production by cells; however, their levels were lower than 
those induced by live bacterial exposure.11
in conclusion, L. rhamnosus was able to induce several 
antiviral effects against HsV-1, which might be through 
different mechanisms including competing with virus for cell 
surface attachment, increasing macrophage viability, following 
stimulation of pro-inflammatory responses. thus, our results 
suggest future in vivo evaluation of L. rhamnosus for increasing 
the immune defense in the cells as a probable candidate for 
HsV-1 infection co-therapy.
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